From IND-enabling studies of biopharmaceuticals to post-commercialization support, EAG scientists find novel scientific ways to answer challenging development questions unique to large molecule development. Our dedicated scientists collaborate with clients as true partners, quickly addressing issues with “we know how” resolve. As a result, they have a proven track record for efficiently advancing complex programs through regulatory milestones.
EAG scientists bring deep insight to the analysis and characterization of Antibody Drug Conjugates (ADCs), monoclonal antibodies, biosimilars, fusion proteins, pegylated proteins and other biotherapeutics.
How do you understand the complexity of biotherapeutics? Turn to EAG. WE KNOW HOW.
HOW WE CAN HELP
From characterization of biopharmaceuticals to cell-based bioassays to routine testing, EAG supports every phase of the product lifecycle.
To enable certain features and improve your experience with us, this site stores cookies on your computer. Please click Continue to provide your authorization and permanently remove this message.